{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:37:24Z","timestamp":1791247044176,"version":"4.1.0"},"reference-count":67,"publisher":"Wiley","issue":"12","license":[{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T00:00:00Z","timestamp":1762905600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"funder":[{"DOI":"10.13039\/100000027","name":"National Institute on Alcohol Abuse and Alcoholism","doi-asserted-by":"publisher","award":["R01AA019720"],"award-info":[{"award-number":["R01AA019720"]}],"id":[{"id":"10.13039\/100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000026","name":"National Institute on Drug Abuse","doi-asserted-by":"publisher","award":["R01DA033289"],"award-info":[{"award-number":["R01DA033289"]}],"id":[{"id":"10.13039\/100000026","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["P30CA016672"],"award-info":[{"award-number":["P30CA016672"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Alcohol, Clinical and Experimental Research"],"published-print":{"date-parts":[[2025,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Tobacco use disorder (TUD) and alcohol use disorder (AUD) frequently co\u2010occur and together are associated with worse prognoses. There are few options for treating both disorders concurrently. This study examined whether the antiepileptic drug topiramate would be effective for treating adults with both AUD and TUD.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>\n                      Participants (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u2009236) from three sites were randomly assigned to receive treatment adherence counseling and either placebo, low\u2010dose topiramate (up to 125\u2009mg\/day), or high\u2010dose topiramate (up to 250\u2009mg\/day) for up to 18\u2009weeks, with a 5\u2010week titration period. The primary outcomes were the mean percentage of heavy drinking days (PHDD) and the smoking continuous abstinence rate with biochemical verification during the last 4\u2009weeks of treatment. Secondary outcomes included quality of life and craving for alcohol and cigarettes. We also conducted post hoc exploratory repeated measures analyses to maximize the use of available data.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>None of the prespecified primary or secondary outcomes differed across medication groups. However, the exploratory analyses indicated that participants treated with the 250\u2009mg dose had lower mean PHDD and drinks per day than those taking the lower dose or placebo. Additionally, participants in both the 125 and 250\u2009mg groups smoked fewer cigarettes per day and reported greater cigarette abstinence than those in the placebo group.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While the primary analyses did not find evidence that topiramate decreases drinking and smoking behavior, likely influenced by a high attrition rate and poor medication adherence, exploratory repeated measures analyses suggest that topiramate 250\u2009mg reduces drinking behavior and that both the 125\u2009mg and 250\u2009mg doses reduce smoking behavior. Future studies that maximize treatment adherence are needed to more definitively determine whether topiramate is an effective treatment for AUD and TUD.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/acer.70193","type":"journal-article","created":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T09:06:47Z","timestamp":1762938407000},"page":"2865-2874","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["High\u2010 and low\u2010dose topiramate for the treatment of persons with alcohol use disorder who smoke cigarettes: A randomized control trial"],"prefix":"10.1111","volume":"49","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-9637","authenticated-orcid":false,"given":"Jason D.","family":"Robinson","sequence":"first","affiliation":[{"name":"Department of Behavioral Science The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6612-1126","authenticated-orcid":false,"given":"Robert M.","family":"Anthenelli","sequence":"additional","affiliation":[{"name":"Department of Psychiatry, University of California, San Diego, Health Sciences Pacific Treatment and Research Center  La Jolla California USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Cinciripini","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maher","family":"Karam\u2010Hage","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yong","family":"Cui","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George","family":"Kypriotakis","sequence":"additional","affiliation":[{"name":"Department of Behavioral Science The University of Texas MD Anderson Cancer Center  Houston Texas USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0604-8377","authenticated-orcid":false,"given":"Nassima Ait\u2010Daoud","family":"Tiouririne","sequence":"additional","affiliation":[{"name":"Department of Psychiatry and Neurobehavioral Sciences University of Virginia School of Medicine  Charlottesville Virginia USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,11,12]]},"reference":[{"key":"e_1_2_8_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.sleep.2008.06.003"},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.2008.02148.x"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.13279"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/archpsyc.1992.01820080007002"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2009.05.025"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12496"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1097\/MLR.0000000000000731"},{"key":"e_1_2_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12411"},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2002.tb02541.x"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsa.1995.56.423"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.yebeh.2004.03.002"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cpr.2013.07.007"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1037\/0893-164X.12.2.101"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02244174"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1465-3362.2009.00054.x"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntab083"},{"key":"e_1_2_8_18_1","first-page":"321","article-title":"Quality of life enjoyment and satisfaction questionnaire: a new measure","volume":"29","author":"Endicott J.","year":"1993","journal-title":"Psychopharmacology Bulletin"},{"key":"e_1_2_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntr137"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02164.x"},{"key":"e_1_2_8_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/ijcp.14594"},{"key":"e_1_2_8_22_1","doi-asserted-by":"crossref","DOI":"10.1136\/bmj-2024-081123","article-title":"CONSORT 2025 statement: updated guideline for reporting randomised trials","volume":"20","author":"Hopewell S.","year":"2025","journal-title":"BMJ"},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12640-011-9275-6"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.15288\/jsad.2017.78.232"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.165.14.1600"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(03)13370-3"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1002\/ddr.430300308"},{"key":"e_1_2_8_28_1","first-page":"282","volume-title":"Handbook of clinical alcoholism treatment","author":"Johnson B.A.","year":"2003"},{"key":"e_1_2_8_29_1","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.168.11.1188"},{"key":"e_1_2_8_30_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.298.14.1641"},{"key":"e_1_2_8_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/jnnp.66.6.759"},{"key":"e_1_2_8_32_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.58"},{"key":"e_1_2_8_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1819.2006.01518.x"},{"key":"e_1_2_8_34_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00213-004-1797-7"},{"key":"e_1_2_8_35_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2013.13081014"},{"key":"e_1_2_8_36_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-020-00945-9"},{"key":"e_1_2_8_37_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.drugalcdep.2013.06.032"},{"key":"e_1_2_8_38_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2002.tb02504.x"},{"key":"e_1_2_8_39_1","first-page":"390","article-title":"Nicotine receptor partial agonists for smoking cessation","volume":"2023","author":"Livingstone\u2010Banks J.","year":"2023","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_8_40_1","doi-asserted-by":"publisher","DOI":"10.1037\/e563232012-001"},{"key":"e_1_2_8_41_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.2007.00592.x"},{"key":"e_1_2_8_42_1","doi-asserted-by":"publisher","DOI":"10.1111\/adb.12192"},{"key":"e_1_2_8_43_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1530-0277.1993.tb00755.x"},{"key":"e_1_2_8_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/ejn.14160"},{"key":"e_1_2_8_45_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.addbeh.2015.06.041"},{"key":"e_1_2_8_46_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamapsychiatry.2017.3544"},{"key":"e_1_2_8_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ntr\/ntt141"},{"key":"e_1_2_8_48_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijerph20054091"},{"key":"e_1_2_8_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF02245485"},{"key":"e_1_2_8_50_1","doi-asserted-by":"publisher","DOI":"10.1176\/appi.ajp.2020.20070993"},{"key":"e_1_2_8_51_1","doi-asserted-by":"publisher","DOI":"10.1111\/acer.14771"},{"key":"e_1_2_8_52_1","article-title":"Opioid antagonists for alcohol dependence","volume":"20","author":"R\u00f6sner S.","year":"2010","journal-title":"Cochrane Database of Systematic Reviews"},{"key":"e_1_2_8_53_1","doi-asserted-by":"publisher","DOI":"10.1093\/oxfordjournals.aje.a113819"},{"key":"e_1_2_8_54_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1360-0443.95.8s2.8.x"},{"key":"e_1_2_8_55_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0306-4522(97)00243-1"},{"key":"e_1_2_8_56_1","doi-asserted-by":"publisher","DOI":"10.1037\/0033-2909.110.3.577"},{"key":"e_1_2_8_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/0163-7258(93)90032-9"},{"issue":"20","key":"e_1_2_8_58_1","first-page":"22","article-title":"The Mini\u2010international neuropsychiatric interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM\u2010IV and ICD\u201010","volume":"59","author":"Sheehan D.V.","year":"1998","journal-title":"The Journal of Clinical Psychiatry"},{"key":"e_1_2_8_59_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1528-1157.2000.tb02171.x"},{"key":"e_1_2_8_60_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1360-0443.1989.tb00737.x"},{"key":"e_1_2_8_61_1","doi-asserted-by":"publisher","DOI":"10.1023\/A:1014844823534"},{"key":"e_1_2_8_62_1","unstructured":"US Department of Health and Human Services. (2017)Common Terminology Criteria for Adverse Events (CTCAE): Version 5.0.https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/docs\/CTCAE_v5_Quick_Reference_5x7.pdf."},{"key":"e_1_2_8_63_1","unstructured":"US Food and Drug Administration. (2023)Smoking Cessation and Related Indications: Developing Nicotine Replacement Therapy Drug Products: Guidance for Industry.https:\/\/www.fda.gov\/media\/167599\/download."},{"key":"e_1_2_8_64_1","unstructured":"US National Institute on Alcohol Abuse and Alcoholism. (2025)Alcohol's Effects on Health: Research\u2010based information on drinking and its impact.https:\/\/www.niaaa.nih.gov\/alcohols\u2010effects\u2010health\/alcohol\u2010drinking\u2010patterns."},{"key":"e_1_2_8_65_1","doi-asserted-by":"publisher","DOI":"10.1037\/0022-3514.54.6.1063"},{"key":"e_1_2_8_66_1","doi-asserted-by":"publisher","DOI":"10.1037\/1064-1297.7.4.354"},{"key":"e_1_2_8_67_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41386-021-00968-w"},{"key":"e_1_2_8_68_1","doi-asserted-by":"publisher","DOI":"10.1038\/npp.2008.99"}],"container-title":["Alcohol, Clinical and Experimental Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acer.70193","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/acer.70193","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/acer.70193","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T08:35:40Z","timestamp":1771317340000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/acer.70193"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,12]]},"references-count":67,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["10.1111\/acer.70193"],"URL":"https:\/\/doi.org\/10.1111\/acer.70193","archive":["Portico"],"relation":{},"ISSN":["2993-7175","2993-7175"],"issn-type":[{"value":"2993-7175","type":"print"},{"value":"2993-7175","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,12]]},"assertion":[{"value":"2025-06-13","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-07","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-11-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}